In the last 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies ITCI stock. Typically employed by major Wall Street banks, these analysts are tasked with understanding a company’s business in order to predict how a stock will trade in the year to come.
|quickly||bit bullish||Moody||bit bearish||recession|
In the last 3 months, 4 analysts have offered 12-month price targets for intracellular therapy. The company’s average price target is $69.5 with a high of $75.00 and a low of $59.00.
Below is a summary of how these 4 analysts rated intracellular therapy over the last 3 months. The higher the number of bullish ratings, the more positive analysts rate the stock, and the higher the number of bearish ratings, the more negative analysts rate the stock.
This is a 6.92% increase from the current average price target of $65.00.
Analysts are experts on banking and financial systems who typically report on specific stocks or within defined sectors. These people research a company’s financial statements, attend conference calls and meetings, and speak with relevant insiders to determine what is called an analyst rating for a stock. Typically, analysts rate each stock once a quarter.
Some analysts also offer forecasts for metrics such as growth forecasts, earnings, and revenue to provide further guidance on the stock. Investors using analyst ratings should note that this particular recommendation is human and may be subject to error.
This article was created by Benzinga’s Automated Content Engine and is editor-reviewed.